Clearside Biomedical (CLSD)

Executive Summary

Clearside Biomedical is a clinical-stage biopharmaceutical company pioneering suprachoroidal injection technology for the treatment of retinal diseases. Its lead asset, CLS-AX (axitinib), is in Phase 3 development for neovascular age-related macular degeneration (wet AMD), with two pivotal trials (ODSIRI) ongoing. The company's suprachoroidal delivery platform aims to enhance drug efficacy and reduce frequent intravitreal injections. Clearside also markets Xipere (triamcinolone acetonide) for suprachoroidal use in uveitis, generating limited revenue. Financial stability is supported by a lean operation and potential milestone payments. Key upcoming events include top-line data from the CLS-AX Phase 3 program, expected in the second half of 2026, which could validate the platform and drive significant value. The company faces high execution risk but has a solid scientific foundation in retinal drug delivery.

Upcoming Catalysts (preview)

• Q3 2026CLS-AX Phase 3 ODSIRI Top-Line Data Readout60% success
• H1 2027Potential BLA Submission for CLS-AX in Wet AMD50% success
• TBDStrategic Partnership or Licensing Deal for CLS-AX or Platform40% success